Sign in or create an account to add this stock to your watchlist.
About AnaptysBio (NASDAQ:ANAB)
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases. It also has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Inc. to develop and commercialize monospecific antibody product candidates targeting TIM-3 (TSR-022), LAG-3 (TSR-033), and PD-1 (TSR-042), as well as a bispecific antibody product candidate targeting PD-1 and LAG-3; and an inflammation partnership with Celgene Corporation to develop an anti-PD-1 agonist antibody (CC-90006) that is in Phase 1 trial. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was founded in 2005 and is based in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ANAB
CUSIPN/A
Phone858-362-6295
Debt
Debt-to-Equity Ratio0.02
Current Ratio17.57
Quick Ratio17.57
Price-To-Earnings
Trailing P/E Ratio-56.47
Forward P/E Ratio-29.24
P/E GrowthN/A
Sales & Book Value
Annual Sales$10 million
Price / Sales201.30
Cash FlowN/A
Price / CashN/A
Book Value$13.09 per share
Price / Book6.54
Profitability
EPS (Most Recent Fiscal Year)($1.52)
Net Income$-30,070,000.00
Net MarginsN/A
Return on Equity-16.60%
Return on Assets-15.05%
Miscellaneous
Employees60
Outstanding Shares23,500,000
AnaptysBio (NASDAQ:ANAB) Frequently Asked Questions
What is AnaptysBio's stock symbol?
AnaptysBio trades on the NASDAQ under the ticker symbol "ANAB."
How were AnaptysBio's earnings last quarter?
AnaptysBio (NASDAQ:ANAB) announced its earnings results on Tuesday, May, 8th. The biotechnology company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.44) by $0.19. During the same quarter last year, the firm posted ($0.75) earnings per share. View AnaptysBio's Earnings History.
What price target have analysts set for ANAB?
8 Wall Street analysts have issued 1-year price targets for AnaptysBio's stock. Their forecasts range from $40.00 to $180.00. On average, they anticipate AnaptysBio's stock price to reach $138.6250 in the next year. View Analyst Ratings for AnaptysBio.
Are investors shorting AnaptysBio?
AnaptysBio saw a increase in short interest in the month of April. As of April 13th, there was short interest totalling 2,515,518 shares, an increase of 43.4% from the March 30th total of 1,754,800 shares. Based on an average daily trading volume, of 578,333 shares, the short-interest ratio is presently 4.3 days. Approximately 15.1% of the shares of the company are short sold.
Who are some of AnaptysBio's key competitors?
Some companies that are related to AnaptysBio include Valeant Pharmaceuticals Intl (VRX), SAGE Therapeutics (SAGE), Alkermes (ALKS), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Catalent (CTLT), Loxo Oncology (LOXO), Agios Pharmaceuticals (AGIO), GALAPAGOS NV/S (GLPG), Dr. Reddy's Laboratories (RDY), United Therapeutics (UTHR), Taro Pharmaceutical Industries (TARO), Hutchison China MediTech (HCM), GW Pharmaceuticals (GWPH) and FibroGen (FGEN).
Who are AnaptysBio's key executives?
AnaptysBio's management team includes the folowing people:
- Mr. Hamza Suria, Pres, CEO & Director (Age 42)
- Prof. Marco Londei M.D., Ph.D., Chief Medical Officer (Age 61)
- Dr. Andrea B. Cubitt, Co-Founder (Age 55)
- Mr. Dominic G. Piscitelli, CFO & Principal Accounting Officer (Age 43)
- Mr. Bob Daniel, Controller
When did AnaptysBio IPO?
(ANAB) raised $60 million in an IPO on Thursday, January 26th 2017. The company issued 4,000,000 shares at $14.00-$16.00 per share. Credit Suisse and Stifel acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
Has AnaptysBio been receiving favorable news coverage?
Press coverage about ANAB stock has trended somewhat positive recently, Accern reports. Accern scores the sentiment of news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. AnaptysBio earned a news impact score of 0.19 on Accern's scale. They also assigned news coverage about the biotechnology company an impact score of 47.20 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
Who are AnaptysBio's major shareholders?
AnaptysBio's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include
FRAZIER HEALTHCARE V, LP
(15.70%),
FRAZIER HEALTHCARE V, LP
(15.70%), FRAZIER HEALTHCARE V, LP (9.93%), BlackRock Inc. (5.96%), OppenheimerFunds Inc. (4.46%) and Redmile Group LLC (2.23%). Company insiders that own AnaptysBio stock include Healthcare Vii LP Frazier, Holdings A/S Novo, Nicholas Lydon and Ventures Vii L P Avalon. View Institutional Ownership Trends for AnaptysBio.
Which major investors are selling AnaptysBio stock?
ANAB stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL, Franklin Resources Inc., VHCP Management II LLC, Citigroup Inc., BNP Paribas Arbitrage SA, JPMorgan Chase & Co., Spark Investment Management LLC and Candriam Luxembourg S.C.A.. Company insiders that have sold AnaptysBio company stock in the last year include Holdings A/S Novo, Nicholas Lydon and Ventures Vii L P Avalon. View Insider Buying and Selling for AnaptysBio.
Which major investors are buying AnaptysBio stock?
ANAB stock was acquired by a variety of institutional investors in the last quarter, including Redmile Group LLC, Millennium Management LLC, Artal Group S.A., Royal Bank of Canada, UBS Group AG, BlackRock Inc., Senzar Asset Management LLC and Guggenheim Capital LLC. Company insiders that have bought AnaptysBio stock in the last two years include Healthcare Vii LP Frazier and Nicholas Lydon. View Insider Buying and Selling for AnaptysBio.
How do I buy shares of AnaptysBio?
Shares of ANAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AnaptysBio's stock price today?
One share of ANAB stock can currently be purchased for approximately $85.44.
How big of a company is AnaptysBio?
AnaptysBio has a market capitalization of $2.06 billion and generates $10 million in revenue each year. The biotechnology company earns $-30,070,000.00 in net income (profit) each year or ($1.52) on an earnings per share basis. AnaptysBio employs 60 workers across the globe.
How can I contact AnaptysBio?
AnaptysBio's mailing address is 10421 PACIFIC CENTER COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-362-6295 or via email at [email protected]
MarketBeat Community Rating for AnaptysBio (ANAB)
MarketBeat's community ratings are surveys of what our community members think about AnaptysBio and other stocks. Vote "Outperform" if you believe ANAB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANAB will underperform the S&P 500 over the long term. You may vote once every thirty days.
AnaptysBio (NASDAQ:ANAB) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
8 Wall Street analysts have issued ratings and price targets for AnaptysBio in the last 12 months. Their average twelve-month price target is $138.6250, suggesting that the stock has a possible upside of 61.83%. The high price target for ANAB is $180.00 and the low price target for ANAB is $40.00. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.88 | 2.88 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $138.6250 | $138.6250 | $124.25 | $86.1250 |
| Price Target Upside: | 61.83% upside | 53.96% upside | 1.74% downside | 21.17% upside |
AnaptysBio (NASDAQ:ANAB) Consensus Price Target History
AnaptysBio (NASDAQ:ANAB) Analyst Ratings History
Show:
(Data available from 5/22/2016 forward)
AnaptysBio (NASDAQ:ANAB) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
AnaptysBio (NASDAQ ANAB) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 20.80%
AnaptysBio (NASDAQ ANAB) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/16/2018 | Nicholas Lydon | Director | Sell | 33,000 | $86.88 | $2,867,040.00 | 301,506 |  |
| 8/21/2017 | Holdings A/S Novo | Major Shareholder | Sell | 356,300 | $21.10 | $7,517,930.00 | 1,936,604 | |
| 8/15/2017 | Holdings A/S Novo | Major Shareholder | Sell | 178,600 | $21.16 | $3,779,176.00 | 2,436,332 | |
| 8/7/2017 | Holdings A/S Novo | Major Shareholder | Sell | 491,294 | $21.12 | $10,376,129.28 | 2,952,527 | |
| 8/3/2017 | Holdings A/S Novo | Major Shareholder | Sell | 70,706 | $23.31 | $1,648,156.86 | 3,009,949 | |
| 7/26/2017 | Ventures Vii L P Avalon | Major Shareholder | Sell | 37,040 | $24.35 | $901,924.00 | | |
| 1/31/2017 | Healthcare Vii L.P. Frazier | Major Shareholder | Buy | 400,000 | $15.00 | $6,000,000.00 | | |
| 1/31/2017 | Nicholas Lydon | Director | Buy | 16,666 | $15.00 | $249,990.00 | 270,957 | |
(Data available from 1/1/2013 forward)
AnaptysBio (NASDAQ ANAB) News Headlines
| Source: |
|
AnaptysBio (NASDAQ:ANAB) SEC Filings
This page is loading this company's SEC Filings. Please wait...
AnaptysBio (NASDAQ:ANAB) Income Statement, Balance Sheet and Cash Flow Statement
AnaptysBio (NASDAQ ANAB) Stock Chart for Tuesday, May, 22, 2018
Loading chart…
